It’s been a buzzy few years for prescription digital therapeutics, marked by bankruptcies, reimbursement policy changes and AI advancements.
At their best, DTx solutions can offer a more personalized, convenient, and cost-effective care experience. But barriers to adoption remain. What are they, and what’s being done about them? Senior Writer Anastassia Gliadkovskaya explores these questions with Joseph Perekupka, CEO of Freespira, and Andy Molnar, SVP of industry affairs for the American Telemedicine Association.
